Ashish Tripathi on pioneering cancer detection and his journey from finance to biotech innovation. [Video]

Ashish Tripathi is the founder and CEO of Tzar Labs and Chairman of
Epigeneres Biotech. The company has made a series of major
breakthroughs in molecular diagnostics and molecular medicines.
Tzar Labs has made a significant breakthrough in early detection of cancer
and is the first pan cancer blood test. He is spearheading the global launch.
Tzar’s highly successful results were published in the April 2021 Springer
journal and Oxford’s Stem Cell in March 2023. They currently have trials in
progress in the NHS and a proof-of-concept study ongoing in the USA. Prior
to this, Ashish was the National Industry Head of Edelweiss IB and has had
20+ years of investment banking /corporate finance, M&A and corporate
strategy experience across Australia, Europe, North America, Asia and Middle East.
He has worked for a variety of MNCs, including Edelweiss, Ernst & Young, Avendus, Fairfax, Mincom, NTT Communications, Deutsche Bank and Deloitte Touché Tohmatsu.
Ashish has also completed his MBA from Melbourne Business School, Australia.
——————————————————————————————————————————-
Tzar specializes in novel onco-biomarkers for screening and early-detection and these biomarkers are associated with pathways and cellular processes such as cancer stemness, microRNAs, metabolism,
epigenetics, sustained growth signaling, etc. Tzar’s highly successful results were published in the April 2021 Springer journal and Oxford’s Stem Cell in March 2023.
Tzar claims multiple global firsts:
All Cancer Detection Blood Test Including solid, hematological and soft tissue sarcomas; Early Detection Diagnosis at Pre-Stage 1 (Stage 0), and Stage 1
Accurate Detection 99% + Specificity for all cancers & all stages*
Cancer Prognostic Blood Test Rule out cancer in the body & predict absence of imminent cancer for the next year (pace of growth of blood-based cancer markers)
All Organ Blood Test Diagnosis of primary organ, and secondary tumour points, pathways and treatment protocols.
The approach, accuracy, and the depth of Tzar’s related bioinformatics information is significantly superior to Grail, Freenome and Guardant, which are multi-billion public companies, as well as other liquid biopsy
companies in this very large and lucrative early cancer detection market.
*Based on Published trial results in the 2021 Springer journal, SCRR.

Links :
https://www.epigeneres.com/news&publications.html

*****************************************************
Visit our website for details about our work :
https://www.nija.world
Please subscribe for regular updates on podcast releases.
Our channels :
YouTube : / @futurefast
Anchor.fm : https://anchor.fm/futurefast
Spotify : https://podcasters.spotify.com/pod/show/futurefast
Substack : https://futurefast.substack.com/
Amazon Podcast :
#digitaltransformation, #operationalexcellence, #energyefficiency, #carbonfootprint, #performancemanagement, #processoptimization, #longevity , #reverseageing, #ageing, #telomeres, #metaverse, #metaverseexplained, #metaverseinfluencer, #Entrepreneurship, #Profits, #Startup, #ZeroCarbon, #ClimateChange, #GreenHydrogen, #ElectricVehicles, #Grid, #ElectricityStorage, #Batteries, #Lithium, #Storage, #Solar, #futurism, #Transhumanism, #EternalLife, #PurposeOfLife